Kidney fibrosis is a critical health problem in the United States because it represents the final common pathway of all chronic kidney diseases yet no biomarkers exist to aid in its diagnosis or measurement of progression. Using cutting edge genomic techniques, we have identified six novel biomarkers of kidney fibrosis and we hypothesize that levels of these biomarkers will accurately reflect kidney fibrosis in humans. In this proposal we have assembled three unique human patient cohorts in which to evaluate these six biomarkers, using histologic kidney fibrosis from kidney biopsy as the gold standard. We will measure biomarker levels in both serum and urine, using controlled and validated assays, and compare biomarker levels with the degree of tubulointerstitial fibrosis observed histologically. The most promising biomarkers will then be measured in a prospective chronic kidney disease cohort, comparing rapid progressors with those who do not progress. Our multidisciplinary team includes individuals with expertise in preclinical fibrosis models, assay development, molecular biology, regulatory compliance, clinical epidemiology, trial design and biostatistics. Together, the proposed experiments represent a rigorous evaluation of these six biomarkers in human chronic kidney disease and will pave the path forward for future studies that will transform clinical trial design and care in nephrology.
Kidney fibrosis is the leading cause of kidney failure worldwide and represents an enormous health burden and unmet medical need. New biomarkers are needed to quantify kidney fibrosis non-invasively in order to identify patients at risk of kidney disease progression and to facilitate clinical trial design. We have discovered six novel biomarkers of kidney fibrosis that are extremely promising for measurement of kidney fibrosis in humans. The experiments in this application are designed to evaluate these six biomarkers in three unique patient cohorts in order to define the biomarker with the greatest promise for future large scale qualification efforts, ideally in collaboration with NIH, regulatory agencies, and industry.
|Leaf, David E; Body, Simon C; Muehlschlegel, Jochen D et al. (2016) Length Polymorphisms in Heme Oxygenase-1 and AKI after Cardiac Surgery. J Am Soc Nephrol 27:3291-3297|
|Ã“ hAinmhire, EoghainÃn; Humphreys, Benjamin D (2016) A Plumbing Solution for Stem Cell-Derived Kidneys. Transplantation 100:3-4|
|Leaf, David E; Srivastava, Anand; Zeng, Xiaoxi et al. (2016) Excessive diagnostic testing in acute kidney injury. BMC Nephrol 17:9|
|Craciun, Florin L; Bijol, Vanesa; Ajay, Amrendra K et al. (2016) RNA Sequencing Identifies Novel Translational Biomarkers of Kidney Fibrosis. J Am Soc Nephrol 27:1702-13|
|Chang-Panesso, Monica; Humphreys, Benjamin D (2015) CD248/Endosialin: A Novel Pericyte Target in Renal Fibrosis. Nephron 131:262-4|
|Kramann, Rafael; Fleig, Susanne V; Schneider, Rebekka K et al. (2015) Pharmacological GLI2 inhibition prevents myofibroblast cell-cycle progression and reduces kidney fibrosis. J Clin Invest 125:2935-51|